FDA approves first generic Actos to treat type 2 diabetes
The FDA has approved the first generic version of Actos (pioglitazone hydrochloride) tablets, used in conjunction with diet and exercise to improve blood glucose control in adults with type 2 diabetes. Mylan Pharmaceuticals, based in Morgantown, W.V., gained FDA approval for 15mg, 30mg and 45mg pioglitazone tablets.
“Controlling blood sugar levels is very important in preventing or reducing the long-term health complications of diabetes,” said Gregory P. Geba, M.D., M.P.H., director of the office of generic drugs in FDA’s Center for Drug Evaluation and Research. “Generic versions of this widely used product will offer affordable treatment options for patients who must manage this chronic and potentially serious condition.”
The most common adverse effects reported by patients using pioglitazone include cold-like symptoms, headache, sinus infection, muscle pain and sore throat. Information about the availability of generic pioglitazone can be obtained from the manufacturer.